These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35831685)

  • 1. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
    Smith KJ; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK
    Infect Dis Ther; 2022 Aug; 11(4):1683-1693. PubMed ID: 35831685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
    Wateska AR; Patricia Nowalk M; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Vaccine; 2022 Nov; 40(50):7312-7320. PubMed ID: 36336526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
    Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
    Wateska AR; Nowalk MP; Altawalbeh SM; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2024 Aug; 72(8):2423-2433. PubMed ID: 38822745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
    Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
    Restivo V; Baldo V; Sticchi L; Senese F; Prandi GM; Pronk L; Owusu-Edusei K; Johnson KD; Ignacio T
    Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Vaccine; 2023 Jul; 41(30):4431-4437. PubMed ID: 37316409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
    Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
    Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Cantarero D; Ocaña D; Onieva-García MÁ; Rodríguez-García J; Gálvez P; Méndez C; Crespo C; López-Ibáñez de Aldecoa A
    Vaccine; 2023 Aug; 41(36):5342-5349. PubMed ID: 37479615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
    Rozenbaum MH; Chilson E; Farkouh R; Huang L; Cane A; Arguedas A; Tort MJ; Snow V; Averin A; Weycker D; Hariharan D; Atwood M
    Infect Dis Ther; 2024 Apr; 13(4):745-760. PubMed ID: 38491269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Vaccine; 2019 Mar; 37(14):2026-2033. PubMed ID: 30846259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
    Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
    Kobayashi M; Pilishvili T; Farrar JL; Leidner AJ; Gierke R; Prasad N; Moro P; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL
    MMWR Recomm Rep; 2023 Sep; 72(3):1-39. PubMed ID: 37669242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.